Sugi Predict

Sugi Predict / Compounds / SCHEMBL13454615

SCHEMBL13454615

SCHEMBL13454615

C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@@]1(C#N)n1ccc(N)nc1=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3A Q14432 3/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ SLC29A1 Q99808 1/20 0.43
▸ LMNA P02545 5/20 0.43
▸ MTOR P42345 2/20 0.43
▸ THRB P10828 1/20 0.43
▸ MDM2 Q00987 1/20 0.43
▸ NCOA1 Q15788 1/20 0.43
▸ NCOA3 Q9Y6Q9 1/20 0.43
▸ CACNA1F O60840 2/20 0.35
▸ ALB P02768 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ CACNA1D Q01668 2/20 0.35
▸ CACNA1S Q13698 2/20 0.35
▸ CACNA1C Q13936 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ DNMT1 P26358 2/20 0.32
▸ GMNN O75496 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13454621 0.89 PDE3A (0.43) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL872890 0.83 PDE3A (0.47) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL13454625 0.82 PDE3A (0.41) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL27999217 0.82 PDE3A (0.52) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL13454608 0.81 ALB (0.37) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL13454638 0.81 POLG (0.46) POLBPOLA1
SCHEMBL13454641 0.80 PDE3A (0.46) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL5070717 0.78 PDE3A (0.47) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL21099932 0.78 PDE4D (0.33) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL13454614 0.78 SLC28A1 (0.41) SLC29A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022165386-A1 LNP AND LMP DELIVERY OF ANTIVIRAL NUCLEOTIDE 5'-PHOSPHATES VIRBIS LLC (US) 2022-08-04 — — WO disclosed
EP-2697241-B1 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES INC (US) 2019-06-12 — — EP disclosed
US-8877733-B2 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (US) 2014-11-04 — — US disclosed
US-8877733-B2 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (US) 2014-11-04 — — US disclosed
US-20120263678-A1 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2012-10-18 — — US disclosed
US-20120263678-A1 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2012-10-18 — — US disclosed
WO-2012142523-A2 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2012-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120263678-A1 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT PNP, NUDT1, TYMP PDE3A 1827/4885PDE4D 2686/4885SLC29A1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.